UK Study Suggests Personalized Medicine May be the Future of Alzheimer’s Disease Treatment
LEXINGTON, Ky. (Oct. 8, 2021) — A recently released paper from the Department of Physiology and Sanders-Brown Center on Aging (SBCoA) at the University of Kentucky College of Medicine suggests that your genetics can influence your response to Alzheimer’s disease pathology.
The laboratory of Donna Wilcock, Ph.D., professor in the Department of Physiology and SBCoA associate director, investigated inflammation in human brain tissue from UK’s Alzheimer’s Disease Research Center. Brain tissue was analyzed from individuals with different forms of the genetic risk factor, apolipoprotein E (ApoE).
ApoE comes in various forms including ApoE2, ApoE3 and ApoE4. ApoE2 is typically thought of as “protective” and reduces the risk of developing Alzheimer’s disease. ApoE3 is the most common form of the gene, while ApoE4 increases the risk and severity of Alzheimer’s disease.
This work, led by graduate student Courtney Kloske, found that individuals with ApoE4 had a reduced inflammatory response to Alzheimer’s disease pathology compared to individuals with ApoE3.
“This finding contradicts data found from mouse work, highlighting the need to always confirm studies in both mouse and then human tissue,” Wilcock said.
“Because of the differing response depending on genotype, targeting inflammation in ApoE4 patients may not be the best approach according to our research,” said Kloske. “This work shows that your genetic makeup may influence your response to certain types of treatment for Alzheimer’s disease.”
The Wilcock lab hopes this work will help contribute to moving treatments closer toward precision medicine.
This work was supported by the 1F31AG069372-01, 1RF1AG057754-01, and P30-AG028383 from the National Institute of Aging. None of this work would have been possible without the research volunteers and clinical investigators at the University of Kentucky Alzheimer’s Disease Research Center. This work is only the responsibility of the authors and does not reflect the official views of the National Institute of Aging.
As the state’s flagship, land-grant institution, the University of Kentucky exists to advance the Commonwealth. We do that by preparing the next generation of leaders — placing students at the heart of everything we do — and transforming the lives of Kentuckians through education, research and creative work, service and health care. We pride ourselves on being a catalyst for breakthroughs and a force for healing, a place where ingenuity unfolds. It's all made possible by our people — visionaries, disruptors and pioneers — who make up 200 academic programs, a $501 million research and development enterprise and a world-class medical center, all on one campus.
In 2022, UK was ranked by Forbes as one of the “Best Employers for New Grads” and named a “Diversity Champion” by INSIGHT into Diversity, a testament to our commitment to advance Kentucky and create a community of belonging for everyone. While our mission looks different in many ways than it did in 1865, the vision of service to our Commonwealth and the world remains the same. We are the University for Kentucky.